Pros | - | Among most bought funds within the category. Larger AUM within category. Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | 3Y returns in the bottom 25% of the category. |
INDMoney rank | - | 7/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 1 Years | 12 Years | ||
Fund Size | 443 Cr | 8114 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹500 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.66% | 0.91% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 57 | 41 | ||
Top 5 Holdings | J.B. Chemicals & Pharmaceuticals Ltd (6.94%) Sun Pharmaceuticals Industries Ltd (6.81%) Fortis Healthcare Ltd (6.69%) Cipla Ltd (4.56%) Laurus Labs Ltd (4.28%) | Sun Pharmaceuticals Industries Ltd (12.29%) Lupin Ltd (7.26%) Divi's Laboratories Ltd (7.01%) Cipla Ltd (6.48%) Apollo Hospitals Enterprise Ltd (5.92%) | ||
No of Sectors | 4 | 1 | ||
Top 3 Sectors | Health (94.88%) Basic Materials (4.55%) Government (0.76%) | Health (100%) | ||
Equity % | 89.07% | 99.47% | ||
Debt % | - | - | ||
P/E | 43.99 | 35.64 | ||
P/B | 7.38 | 5.65 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 4.83% | 3.63% | ||
3-Month Return | -0.4% | -4.1% | ||
6-Month Return | 10.98% | 3.82% | ||
1-Year Return | 11.89% | 2.29% | ||
3-Year Return | - | 22.55% | ||
5-Year Return | - | 19.37% |
Sharpe | - | 0.95 | ||
Alpha | - | -0.12 | ||
Beta | - | 0.91 | ||
Standard Deviation | - | 15.23 | ||
Information Ratio | - | -0.44 |
Description | WhiteOak Capital Pharma and Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Piyush Baranwal,Dheeresh Pathak,Trupti Agrawal,Ashish Agrawal,Ramesh Mantri | Sailesh Raj Bhan,Kinjal Desai |